Skip Navigation


Annals of Oncology Advance Access originally published online on June 18, 2009
Annals of Oncology 2009 20(10):1682-1687; doi:10.1093/annonc/mdp054
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/10/1682    most recent
mdp054v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Montero, A. J.
Right arrow Articles by Tannir, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montero, A. J.
Right arrow Articles by Tannir, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

urogenital tumors

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival

A. J. Montero1,{dagger},{ddagger}, C. M. Diaz-Montero2,{dagger},{ddagger}, R. E. Millikan1,*, J. Liu3, K.-A. Do3, S. Hodges1, E. Jonasch1, B. W. McIntyre2, P. Hwu4 and N. Tannir1

1 Departments of Genitourinary Medical Oncology
2 Immunology
3 Biostatistics and Applied Mathematics
4 Melanoma, University of Texas MD Anderson Cancer Center, Houston, USA

* Correspondence to: Dr R. Millikan, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Unit 1374, 1155 Pressler Boulevard, Houston, TX 77030, USA. Tel: +1-713-792-2830; Fax: +1-713- 745-1625; E-mail: remillika{at}mdanderson.org

Background: To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-{alpha} (IFN-{alpha}).

Patients and methods: Serum CAF levels were measured in 103 patients treated on a randomized trial with IFN-{alpha} 0.5 million units (MU) twice daily or 5 MU daily. Concentrations of 17 analytes were determined by multiplex bead immunoassays [vascular endothelial growth factor A (VEGFA) and several cytokines] or enzyme-linked immunosorbent assay (basic fibroblast growth factor). We used proportional hazards models to evaluate the effect of CAF levels and clinical factors on OS.

Results: Pretreatment serum interleukin (IL) 5, IL-12 p40, VEGFA, and IL-6 levels and Memorial Sloan-Kettering Cancer Center risk grouping independently correlated with OS, with hazard ratios of 2.33, 2.00, 2.07, 1.82, and 0.39, respectively (concordance index = 0.69 for the combined model versus 0.60 for the CAF model versus 0.52 for the clinical model). Based on an index derived from these five risk factors (RFs), patients with 0–2 RF had a median OS time of 32 months versus 9 months for patients with 3–5 RF (P < 0.0001).

Conclusions: Serum CAF profiling contributes to prognostic evaluation in mRCC and helps to identify a subset of patients with 20% 5-year OS.

Key words: angiogenesis, cytokine profiling, inflammation, interferon-{alpha}, metastatic renal cell carcinoma, multiplex bead immunoassays

{dagger} Both authors contributed equally.

{ddagger} Present address: Department of Internal Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Received for publication November 18, 2008. Revision received February 5, 2009. Accepted for publication February 11, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.